Recent advances in Ebolavirus vaccine development

Human Vaccines

Volumn 6, Issue 6, 2010, Pages 439-449

  Richardson, Jason S ^a   Dekker, Joseph D ^b   Croyle, Maria A ^b   Kobinger, Gary P ^a,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Ebolavirus; Formulations; Route; Vaccines; Virus

Indexed keywords

DNA VACCINE; DROTRECOGIN; EBOLA VACCINE; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTICOAGULATION; BIOLOGICAL WARFARE; DRUG FORMULATION; DRUG RESEARCH; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FATALITY; HUMAN; NONHUMAN; PARAINFLUENZA VIRUS 3; PATHOGENESIS; REVIEW; VESICULAR STOMATITIS VIRUS; VIRUS PARTICLE; VIRUS REPLICATION;

EID: 77956673572     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.6.11097     Document Type: Review

References (193)

1. th Report of the International Commitee on Taxonomy of Viruses In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Filoviridae. London: Elsevier/Academic Press 2004.
2. Bowen ET, Platt GS, Lloyd G, Raymond RT, Simpson DI. A comparative study of strains of Ebola virus isolated from Southern Sudan and northern Zaire in 1976. J Med Virol 1980; 6:129-38. (Pubitemid 11188426)
3. Buchmeier MJ, DeFries RU, McCormick JB, Kiley MP. Comparative analysis of the structural polypeptides of Ebola viruses from Sudan and Zaire. J Infect Dis 1983; 147:276-81.
4. Cox NJ, McCormick JB, Johnson KM, Kiley MP. Evidence for two subtypes of Ebola virus based on oligonucleotide mapping of RNA. J Infect Dis 1983; 147:272-5.
5. Kiley MP, Bowen ET, Eddy GA, Isaacson M, Johnson KM, McCormick JB, et al. Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology 1982; 18:24-32.
6. Kiley MP, Wilusz J, McCormick JB, Keene JD. Conservation of the 3′ terminal nucleotide sequences of Ebola and Marburg virus. Virology 1986; 149:251-4. (Pubitemid 16127823)
7. Martini GA, Siegert R. Marburg Virus Disease. Berlin: Springer-Verlag 1971.
8. Murphy FA, van der Groen G, Whitfield SG, Lange JV. Ebola and Marburg virus morphology and taxonomy. In: Pattyn S, ed. Ebola Virus Haemorrhagic Fever. Amsterdam: Elsevier/North Holland 1978; 61-84.
9. Pattyn S. Virological diagnosis of Ebola virus infection. In: Pattyn S, ed. Ebola Virus Haemorrhagic Fever. Amsterdam: Elsevier/North Holland 1978; 85-9.
10. Regnery RL, Johnson KM, Kiley MP. Virion nucleic acid of Ebola virus. J Virol 1980; 36:465-9.
11. Sanchez A, Kiley MP. Identification and analysis of Ebola virus messenger RNA. Virology 1987; 157:414-20. (Pubitemid 17047696)
12. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola Viruses. In: Knipe DM, Howley PM, eds. Fields Virology: Lippincott Williams & Wilkins 2007.
13. th Report of the International Committee on Taxonomy of Viruses. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, eds. Filoviridae. London: Elsvier/Academic Press 2004.
14. Le Guenno B, Formenty P, Boesch C. Ebola virus outbreaks in the Ivory Coast and Liberia, 1994-1995. Curr Top Microbiol Immunol 1999; 235:77-84.
15. Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, Hall WC, Peters CJ. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990; 335:502-5.
16. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4:1000212.
17. WHO. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. 1978. http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=307455. Accessed on 2009.
18. WHO. Ebola haemorrhagic fever in Zaire, 1976. 1978. http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=307456. Accessed on 2009.
19. Siegert R, Shu HL, Slenczka W. Isolation and identification of the "Marburg virus". Ger Med Mon 1968; 13:514-8.
20. Siegert R, Shu HL, Slenczka W, Peters D, Muller G. On the etiology of an unknown human infection originating from monkeys. Dtsch Med Wochenschr 1967; 92:2341-3.
21. Peterson AT, Bauer JT, Mills JN. Ecologic and geographic distribution of filovirus disease. Emerg Infect Dis 2004; 10:40-7.
22. Peterson AT, Lash RR, Carroll DS, Johnson KM. Geographic potential for outbreaks of Marburg hemorrhagic fever. Am J Trop Med Hyg 2006; 75:9-15. (Pubitemid 351627562)
23. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-6. (Pubitemid 41740557)
24. Feldmann H, Wahl-Jensen V, Jones SM, Stroher U. Ebola virus ecology: a continuing mystery. Trends Microbiol 2004; 12:433-7. (Pubitemid 39286118)
25. Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis 1996; 2:321-5.
26. WHO. Ebola outbreak contained in Uganda. 2008. http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list- uids=307456. Accessed on 2009.
27. Formenty P, Boesch C, Wyers M, Steiner C, Donati F, Dind F, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Cote d'Ivoire. J Infect Dis 1999; 179:120-6.
28. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 1999; 179:48-53.
29. Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peters CJ. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Arch Virol Suppl 1996; 11:115-34.
30. Fisher-Hoch SP, Brammer TL, Trappier SG, Hutwagner LC, Farrar BB, Ruo SL, et al. Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis 1992; 166:753-63.
31. Elliott LH, Kiley MP, McCormick JB. Descriptive analysis of Ebola virus proteins. Virology 1985; 147:169-76.
32. Volchkov VE, Volchkova VA, Chepurnov AA, Blinov VM, Dolnik O, Netesov SV, Feldmann H. Characterization of the L gene and 5′ trailer region of Ebola virus. J Gen Virol 1999; 80:355-62. (Pubitemid 29095195)
33. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol 2003; 77:1793-800. (Pubitemid 36109991)
34. Becker S, Rinne C, Hofsass U, Klenk HD, Muhlberger E. Interactions of Marburg virus nucleocapsid proteins. Virology 1998; 249:406-17. (Pubitemid 28460892)
35. Klenk HD, Feldmann H. Modulation of innate immunity by filoviruses. In: Basler CF, Palese P, eds. Ebola and Marburg Viruses-Molecular and Cellular Biology. Norfol, Va: Horizon Bioscience 2004; 305-49.
36. Feldmann H, Slenczka W, Klenk HD. Emerging and reemerging of filoviruses. In: Schwarz TF, Siegl G, eds. Imported Virus Infectons Vienna: Archives of Virology Supplement 1996; 77-100.
37. Sanchez A, Trappier SG, Stroher U, Nichol ST, Bowen MD, Feldmann H. Variation in the glycoprotein and VP35 genes of Marburg virus strains. Virology 1998; 240:138-46. (Pubitemid 28394132)
38. 1 in viral entry. J Virol 2005; 79:4793-805.
39. Kuhn JH, Radoshitzky SR, Guth AC, Warfield KL, Li W, Vincent MJ, et al. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J Biol Chem 2006; 281:15951-8. (Pubitemid 43848488)
40. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 1999; 73:6024-30. (Pubitemid 29274889)
41. Becker Y. Retrovirus and Filovirus "immunosuppressive motif" and the evolution of virus pathogenicity in HIV-1, HIV-2 and Ebola viruses. Molecular Evolution of Viruses: Past and Present. Norwell, Massachusetts: Kluwer Academic Publisher 1996; 119-23.
42. Benit L, Dessen P, Heidmann T. Identification, phylogeny and evolution of retroviral elements based on their envelope genes. J Virol 2001; 75:11709-19. (Pubitemid 33063262)
43. Kuhn JH. Filoviruses A Compendium of 40 Years of Epidemiological, Clinical and Laboratory Studies. In: Calisher CH, ed. Archieves of Virology. Austria: Springer-Verlag/Wien 2008.
44. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002; 76:6841-4. (Pubitemid 34633551)
45. Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 1994; 199:469-73. (Pubitemid 24168987)
46. Feldmann H, Will C, Schikore M, Slenczka W, Klenk HD. Glycosylation and oligomerization of the spike protein of Marburg virus. Virology 1991; 182:353-6.
47. Geyer H, Will C, Feldmann H, Klenk HD, Geyer R. Carbohydrate structure of Marburg virus glycoprotein. Glycobiology 1992; 2:299-312.
48. Volchkov VE. Processing of the Ebola virus glycoprotein. Curr Top Microbiol Immunol 1999; 235:35-47.
49. Sanchez A, Yang ZY, Xu L, Nabel GJ, Crews T, Peters CJ. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J Virol 1998; 72:6442-7. (Pubitemid 28323957)
50. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci USA 1998; 95:5762-7. (Pubitemid 128632309)
51. Volchkov VE, Volchkova VA, Stroher U, Becker S, Dolnik O, Cieplik M, et al. Proteolytic processing of Marburg virus glycoprotein. Virology 2000; 268:1-6. (Pubitemid 30131964)
52. Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000; 287:1664-6. (Pubitemid 30127770)
53. Hevey M, Negley D, Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology 2003; 314:350-7. (Pubitemid 37153323)
54. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251:28-37. (Pubitemid 28527716)
55. Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 1985; 147:199-209. (Pubitemid 16231737)
56. Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB, Vogel P, et al. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med 1997; 121:805-19.
57. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70. (Pubitemid 37466478)
58. Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol 1998; 22:3-17.
59. Geisbert TW, Jahrling PB, Hanes MA, Zack PM. Association of Ebola-related Reston virus particles and antigen with tissue lesions of monkeys imported to the United States. J Comp Pathol 1992; 106:137-52.
60. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, Hensley LE. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371-82. (Pubitemid 37474154)
61. Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995; 346:1669-71. (Pubitemid 26003325)
62. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, Jahrling PB. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120:140-55. (Pubitemid 26058522)
63. Murphy FA, Simpson DI, Whitfield SG, Zlotnik I, Carter GB. Marburg virus infection in monkeys. Ultrastructural studies. Lab Invest 1971; 24:279-91.
64. Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179:199-202.
65. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999; 235:97-116.
66. Zaki SR, Shieh WJ, Greer PW, Goldsmith CS, Ferebee T, Katshitshi J, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179:36-47.
67. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005; 37:1560-6. (Pubitemid 40719635)
68. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, Debre P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5:423-6. (Pubitemid 29180581)
69. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 2000; 5:5-7.
70. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171-86.
71. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol 2004; 17:390-400.
72. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003; 188:1613-7. (Pubitemid 38010670)
73. Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004; 10:110-21.
74. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29. (Pubitemid 38010671)
75. Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNFalpha and inhibit poly-IC-induced IFNalpha in vitro. Virology 2001; 284:20-5. (Pubitemid 32476692)
76. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4:487-98.
77. Schnittler HJ, Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages? Clin Infect Dis 1998; 27:404-6.
78. Schnittler HJ, Feldmann H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr Top Microbiol Immunol 1999; 235:175-204.
79. Schnittler HJ, Feldmann H. Viral hemorrhagic fever - a vascular disease? Thromb Haemost 2003; 89:967-72.
80. Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 2001; 75:11025-33. (Pubitemid 33031570)
81. Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, Schnittler HJ. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 2005; 79:10442-50. (Pubitemid 41098584)
82. CDC. Centers for Disease Control and Prevention/National Institutes of Health. Biosaftey in Microbiological and Biomedical Laboratories. Washington DC: U.S. Government Printing Office 1999; 93-8395.
83. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400.
84. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8. (Pubitemid 37548417)
85. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007; 196:390-9.
86. Chupurnov AA, Chernukhin IV, Ternovoi VA, Kudoiarova NM, Makhova NM, Azaev M, Smolina MP. Attempts to develop a vaccine against Ebola fever. Vopr Virusol 1995; 40:257-60.
87. Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol 1996; 44:111-8.
88. Ignat'ev GM, Agafonov AP, Strel'tsova MA, Kuz'min VA, Mainagasheva GI, Spirin GV, Chernyi NB. A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus. Vopr Virusol 1991; 36:421-3.
89. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980; 2:1294-5.
90. Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, Krasnianskii VP. The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever. Vopr Virusol 1994; 39:82-4.
91. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8:503-7. (Pubitemid 34533328)
92. Bazhutin NB, Belanov EF, Spiridonov VA, Voitenko AV, Krivenchuk NA, Krotov SA, et al. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. Vopr Virusol 1992; 37:153-6.
93. Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985; 152:887-94.
94. Baskerville A, Bowen ET, Platt GS, McArdell LB, Simpson DI. The pathology of experimental Ebola virus infection in monkeys. J Pathol 1978; 125:131-8. (Pubitemid 8400311)
95. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125:243-53. (Pubitemid 34023737)
96. Halfmann P, Ebihara H, Marzi A, Hatta Y, Watanabe S, Suresh M, et al. Replication-deficient ebolavirus as a vaccine candidate. J Virol 2009; 83:3810-5.
97. Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246:134-44. (Pubitemid 28384067)
98. Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 2000; 55:1-74.
99. Riemenschneider J, Garrison A, Geisbert J, Jahrling P, Hevey M, Negley D, et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 2003; 21:4071-80.
100. Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res 2003; 92:187-93.
101. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. Immunization for Ebola virus infection. Nat Med 1998; 4:37-42.
102. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
103. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77.
104. Rao M, Bray M, Alving CR, Jahrling P, Matyas GR. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002; 76:9176-85. (Pubitemid 34919876)
105. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195:593-602. (Pubitemid 34461504)
106. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci USA 2000; 97:13871-6.
107. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 2001; 75:5205-14. (Pubitemid 32448543)
108. Kolesnikova L, Berghofer B, Bamberg S, Becker S. Multivesicular bodies as a platform for formation of the Marburg virus envelope. J Virol 2004; 78:12277-87. (Pubitemid 39458747)
109. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76:4855-65. (Pubitemid 34441691)
110. Swenson DL, Warfield KL, Kuehl K, Larsen T, Hevey MC, Schmaljohn A, et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol 2004; 40:27-31. (Pubitemid 38083355)
111. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of ebola virus matrix protein VP40. Virology 2001; 283:1-6.
112. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42.
113. Wahl-Jensen V, Kurz SK, Hazelton PR, Schnittler HJ, Stroher U, Burton DR, Feldmann H. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005; 79:2413-9.
114. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100:15889-94. (Pubitemid 38021085)
115. Watanabe S, Watanabe T, Noda T, Takada A, Feldmann H, Jasenosky LD, Kawaoka Y. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol 2004; 78:999-1005. (Pubitemid 38067621)
116. + T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175:1184-91.
117. Warfield KL, Perkins JG, Swenson DL, Deal EM, Bosio CM, Aman MJ, et al. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med 2004; 200:169-79.
118. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196:430-7.
119. Chepurnov AA, Ternovoi VA, Dadaeva AA, Dmitriev IP, Sizikova LP, Volchkov VE, et al. Immunobiological properties of vp24 protein of Ebola virus expressed by recombinant vaccinia virus. Vopr Virusol 1997; 42:115-20.
120. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19:142-53. (Pubitemid 30618964)
121. Nazir SA, Metcalf JP. Innate immune response to adenovirus. J Investig Med 2005; 53:292-304.
122. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:177.
123. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009; 4:5308.
124. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 2006; 346:394-401. (Pubitemid 43357883)
125. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15:35-46. (Pubitemid 38147187)
126. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005; 79:14161-8.
127. Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006; 80:1688-99.
128. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 2008; 16:965-71.
129. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 2007; 196:413-20.
130. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:3548.
131. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. Nonsegmented negative-strand viruses as vaccine vectors. J Virol 2006; 80:10293-306.
132. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
133. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
134. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007; 3:2.
135. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 2009; 83:7296-304.
136. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 2009; 4:5547.
137. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, Leung A, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 2008; 4:1000225.
138. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 2006; 80:2267-79. (Pubitemid 43271533)
139. Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 2008; 377:255-64. (Pubitemid 351822376)
140. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81:6379-88. (Pubitemid 46878044)
141. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128:163-8. (Pubitemid 34451194)
142. Heffernan RT, Pambo B, Hatchett RJ, Leman PA, Swanepoel R, Ryder RW. Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooue-Ivindo region, Northeastern Gabon, 1997. J Infect Dis 2005; 191:964-8.
143. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179:177-87.
144. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001; 124:453-60.
145. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, Rollin PE. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load and nitric oxide levels. J Virol 2004; 78:10370-7. (Pubitemid 39258362)
146. Lajeunesse M, Zhang Q, Finn A. Mucosal immunity to infections and its importance in future vaccinology. Adv Exp Med Biol 2004; 549:13-22. (Pubitemid 38968175)
147. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170:5636-43. (Pubitemid 36617855)
148. Basset C, Holton J, O'Mahony R, Roitt I. Innate immunity and pathogen-host interaction. Vaccine 2003; 21:12-23.
149. Zhou D, Ertl HC. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opin Biol Ther 2006; 6:63-72. (Pubitemid 43049347)
150. Arvin AM, Greenberg HB. New viral vaccines. Virology 2006; 344:240-9.
151. Bramwell VW, Eyles JE, Oya Alpar H. Particulate delivery systems for biodefense subunit vaccines. Adv Drug Deliv Rev 2005; 57:1247-65.
152. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006; 58:68-89.
153. Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004; 5:460-4.
154. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148-58.
155. Jiang P, Liu Y, Yin X, Yuan F, Nie Y, Luo M, et al. Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120. Biochem Biophys Res Commun 2006; 339:526-32. (Pubitemid 41739699)
156. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 2001; 75:11079-87. (Pubitemid 33031574)
157. Publicover J, Ramsburg E, Rose JK. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005; 79:13231-8. (Pubitemid 41508138)
158. Reuter JD, Vivas-Gonzalez BE, Gomez D, Wilson JH, Brandsma JL, Greenstone HL, et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 2002; 76:8900-9. (Pubitemid 34864084)
159. Schlereth B, Buonocore L, Tietz A, Meulen Vt V, Rose JK, Niewiesk S. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol 2003; 84:2145-51. (Pubitemid 36927245)
160. Xing Z, Lichty BD. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 2006; 86:211-7.
161. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 2006; 14:662-72. (Pubitemid 44480754)
162. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998; 72:4704-11. (Pubitemid 28215645)
163. Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007; 196:404-12.
164. Barouch DH. Rational design of gene-based vaccines. J Pathol 2006; 208:283-9.
165. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel) 2005; 121:153-63.
166. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006; 344:230-9. (Pubitemid 41814465)
167. Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliv Rev 2005; 57:1381-91. (Pubitemid 40791117)
168. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004; 21:201-30.
169. Fasbender A, Zabner J, Chillon M, Moninger TO, Puga AP, Davidson BL, Welsh MJ. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem 1997; 272:6479-89. (Pubitemid 27118128)
170. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi Viruses 2008; 2:243-9.
171. Raczka E, Kukowska-Latallo JF, Rymaszewski M, Chen C, Baker JR Jr. The effect of synthetic surfactant Exosurf on gene transfer in mouse lung in vivo. Gene Ther 1998; 5:1333-9. (Pubitemid 28482660)
172. Pifferi G, Santoro P, Pedrani M. Quality and functionality of excipients. Farmaco 1999; 54:1-14.
173. Slutter B, Plapied L, Fievez V, Sande MA, des Rieux A, Schneider YJ, et al. Mechanistic study of the adjuvant effect of biodegradable nanoparticles in mucosal vaccination. J Control Release 2009; 138:113-21.
174. Prego C, Fabre M, Torres D, Alonso MJ. Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm Res 2006; 23:549-56.
175. Vaccine Adjuvants and Delivery Systems. Hoboken: John Wiley & Sons, Inc 2007.
176. Crawford LM. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Federal Register 2002; 67:37988-98.
177. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009; 7:393-400.
178. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol 2001; 75:2660-4.
179. Gupta M, Mahanty S, Greer P, Towner JS, Shieh WJ, Zaki SR, et al. Persistent infection with ebola virus under conditions of partial immunity. J Virol 2004; 78:958-67. (Pubitemid 38067617)
180. Gupta M, Greer P, Mahanty S, Shieh WJ, Zaki SR, Ahmed R, Rollin PE. CD8-mediated protection against Ebola virus infection is perforin dependent. J Immunol 2005; 174:4198-202. (Pubitemid 40395999)
181. Bradfute SB, Warfield KL, Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol 2008; 180:4058-66.
182. WHO. Ebola haemorrhagic fever in Zaire, 1976. 1978. http://www.ncbi.nlm. nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt= Citation&list-uids=307456. Accessed on 2009.
183. WHO. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. 1978. http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=307455. Accessed on 2009.
184. Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T, Berquist H. Ebola hemorrhagic fever: Tandala, Zaire, 1977-1978. J Infect Dis 1980; 142:372-6.
185. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in Southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983; 61:997-1003.
186. Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, Ngoc MT, et al. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997: epidemiologic and health control issues. J Infect Dis 1999; 179:65-75.
187. Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kerstiens B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 1791:76-86.
188. Okware SI, Omaswa FG, Zaramba S, Opio A, Lutwama JJ, Kamugisha J, et al. An outbreak of Ebola in Uganda. Trop Med Int Health 2002; 7:1068-75.
189. Formenty P, Libama F, Epelboin A, Allarangar Y, Leroy E, Moudzeo H, et al. Outbreak of Ebola hemorrhagic fever in the Republic of the Congo, 2003: a new strategy?. Med Trop (Mars) 2003; 63:291-5.
190. WHO. Outbreak news. Ebola virus haemorrhagic fever, Democratic Republic of the Congo - update. 2007. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=17918654. Accessed on 2009.
191. WHO. Outbreak of Ebola haemorrhagic fever in Yambio, south Sudan, April-June 2004. 2005. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=16285261. Accessed on 2009.
192. CDC. Known Cases and Outbreaks of Ebola Hemorrhagic Fever, in Chronological Order 2009. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/ ebola/ebolatable.htm. Accessed on 2009.
193. WHO. End of Ebola outbreak in the Democratic Republic of the Congo. 2009. http://www.who.int/csr/don/archive/disease/ebola-haemorrhagic-fever/en/index. html. Accessed on 2009.